{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:03:09Z","timestamp":1793462589598,"version":"4.5.0"},"reference-count":101,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2022,11,2]]},"DOI":"10.1080\/14740338.2022.2147924","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T11:51:08Z","timestamp":1668685868000},"page":"1365-1378","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Fluoroquinolones: old drugs, putative new toxicities"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-9477","authenticated-orcid":false,"given":"Cecilia","family":"Bove","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, Kinsley school of Engineering, Science and Technology, York College of Pennsylvania, 441 Country Club Road, York, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-2966","authenticated-orcid":false,"given":"Robert A.","family":"Baldock","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomedical Science, University of Portsmouth, Faculty of Science and Health, St. Michael\u2019s Building, White Swan Road, PO1 2DT, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Champigneulle","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences (CPOS), University of South Carolina Schools of Pharmacy and Engineering and the SmartState Center for Medication Safety and Efficacy, Columbia, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences (CPOS), University of South Carolina Schools of Pharmacy and Engineering and the SmartState Center for Medication Safety and Efficacy, Columbia, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences (CPOS), University of South Carolina Schools of Pharmacy and Engineering and the SmartState Center for Medication Safety and Efficacy, Columbia, SC, USA"},{"name":"Beckman Research Institute (BRI) of City of Hope and the Department of Comparative Medicine and Evidence Based Medicine, City of Hope Comprehensive Cancer Center, Duarte, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg208"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.4085\/1062-6050-49.2.09"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.05.027"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.12.006"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2013.12.009"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Z429"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.12788\/jcso.0167"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000197124.31174.7e"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix032"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010077"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5389"},{"key":"cit0012","unstructured":"Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes [Internet]. FDA; 2019 [cited 2022 May 12]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side."},{"key":"cit0013","unstructured":"Food and Drug Administration. FDA briefing document - the benefits and risks of systemic fluoroquinolone antibacterial drugs for the treatment of Acute Bacterial Sinusitis (ABS), Acute Bacterial Exacerbation Of Chronic Bronchitis In Patients who Have Chronic Obstructive Pulmonary Disease (ABECB-COPD), and Uncomplicated Urinary Tract Infections (uUTI). [Internet]. 2015 [cited 2022 Mar 24]. Available from: https:\/\/web.archive.org\/web\/20160208032716\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM477657.pdf."},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8023935"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-03267-5"},{"key":"cit0016","unstructured":"Food and Drug Administration. FDA advisory committee 2013 report FQ toxicity. Internet]. 2013. Available from: No longer available online."},{"issue":"5","key":"cit0017","first-page":"461","volume":"34","author":"Tsai W-C","year":"2011","journal-title":"Chang Gung Med J"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2018.08.079"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-3-10"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.671222"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-021-02258-1"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.02.006"},{"issue":"5","key":"cit0023","first-page":"1178","volume":"50","author":"Lawrence JW","year":"1996","journal-title":"Mol Pharmacol"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1177\/1087057110373547"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006055"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1021\/tx700210j"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky793"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2018.1804"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303360110"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701411"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.4.457"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.3109\/15376516.2015.1026008"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.6.1356"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1831"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.427"},{"key":"cit0036","first-page":"31","volume":"4","author":"Moghimi A","year":"2013","journal-title":"Basic Clin Neurosci"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1982.tb05051.x"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1159\/000115131"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.1.168"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004685"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2006.01.009"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2017.08.005"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90571-6"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.10.032"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.15.1801"},{"key":"cit0047","unstructured":"Food and Drug Administration. FDA\u2019s center for drug evaluation and research. Application for cipro as a supplemental new drug application. (1) [Internet]. 2004 [cited 2022 May 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/019537_S051_CIPRO.pdf."},{"key":"cit0048","unstructured":"Madigan L. Illinois attorney general Lisa Madigan press release. Madigan, public citizen petition FDA for \u201cBlack Box\u201d warning for certain popular antibiotics. Dated August 29, 2006, [Internet]. 2006. [cited 2022 May 23]. Available from: https:\/\/illinoisattorneygeneral.gov\/pressroom\/2006_08\/20060829.html."},{"key":"cit0049","volume":"337","author":"Tanne JH","year":"2008","journal-title":"BMJ"},{"key":"cit0050","unstructured":"Sasich LD, Wolfe SM. Petition to require a warning on all fluoroquinolone antibiotics [Internet]. Public Citiz. 1996 [cited 2022 May 17]. Available from: https:\/\/www.citizen.org\/article\/petition-to-require-a-warning-on-all-fluoroquinolone-antibiotics\/."},{"key":"cit0051","unstructured":"Food and Drug Administration. FDA\/CDER response to Illinois attorney general\u2019s office and public citizen health research group\u2014partial approval\/denial letter. (no longer available on the internet) [Internet]. 2006. [cited 2022 Apr 20]. Available from: http:\/\/www.regulations.gov\/-!documentDetail;D=FDA-2006-P-0390-0005."},{"key":"cit0052","unstructured":"Food and Drug Administration. FDA. Center for drug evaluation and research. Approval package for ciprofloxacin hydrochloride. Application number 19-537\/S-068. [Internet]. 2008 [cited 2022 May 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/019537Orig1s068.pdf."},{"key":"cit0053","unstructured":"Food and Drug Administration. FDA. Center for drug evaluation and research. Letter to ortho McNeil-Janssen pharmaceutical incorporated re\/ proposed revised labeling. [Internet]. 2008. [cited 2022 May 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2008\/020634s052,%20020635s057,021721s020ltr%20.pdf."},{"key":"cit0054","unstructured":"Bayer P. Bayer health care pharmaceuticals. medication guide: CIPRO. Revised. [Internet]. 2008. [cited 2022 May 17]. Available from: https:\/\/www.fda.gov\/media\/73412\/download."},{"key":"cit0055","unstructured":"Janssen Ortho LLC. Medication Guide: LEVAQUIN. Revised [Internet]. 2008. [cited 2022 May 17]. Available from: https:\/\/www.fda.gov\/media\/75781\/download."},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1085968"},{"key":"cit0057","volume-title":"CIPRO (ciprofloxacin hydrochloride) Revised","author":"Food and Drug Administration","year":"2016"},{"key":"cit0058","unstructured":"The Canadian Press. Health Canada asks for tendon warning for some antibiotics | CBC News [Internet]. CBC. 2008. [cited 2022 May 23]. Available from: https:\/\/www.cbc.ca\/news\/science\/health-canada-asks-for-tendon-warning-for-some-antibiotics-1.735102."},{"key":"cit0059","unstructured":"Therapeutics Initiative. Drug safety advisories: a need for international coordination. [Internet]. 2020. [cited 2022 May 23]. Available from: https:\/\/www.ti.ubc.ca\/2020\/12\/03\/128-drug-safety-advisories-a-need-for-international-coordination\/."},{"key":"cit0060","unstructured":"Japan\u2019s Pharmaceutical and Medical Devices Agency. Summary of investigation results: fluoroquinolones (oral and injectable dosage forms). [Internet]. 2019. [cited 2022 Mar 28]. Available from: https:\/\/www.pmda.go.jp\/files\/000227480.pdf."},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7349.1306"},{"key":"cit0062","unstructured":"Medsafe. Quinolones- a tendency to rupture. Dated September 2012. [Internet]. 2012. [cited 2022 May 17]. Available from: https:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/QuinolonesSept2012.htm."},{"key":"cit0063","unstructured":"Singer S. FDA\u2019s office of safety and epidemiology post-marketing safety review: peripheral neuropathy associated with levofloxacin. (no longer available on the internet). 2001"},{"key":"cit0064","unstructured":"Boxwell D, Cao K, Gilbert J, et al. Disabling peripheral neuropathy associated with system fluoroquinolone exposure. Internal pharmacovigilance review from the division of pharmacovigilance of the food and drug administration center for drug evaluation research\u2019s office of surveillance and epidemiology. (no longer available on the internet). 2013"},{"key":"cit0065","unstructured":"Food and Drug Administration. FDA\u2019s center for drug evaluation and research. Application for Cipro as a supplemental new drug application. (2) [Internet]. 2004. [cited 2022 May 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/019537_S053_CIPRO.pdf."},{"key":"cit0066","unstructured":"Food and Drug Administration. FDA drug safety communications. FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. [Internet]. 2013. [cited 2022 May 23]. Available from: https:\/\/www.fda.gov\/media\/86575\/download."},{"key":"cit0067","unstructured":"European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products [Internet]. Eur. Med. Agency. 2018. [cited 2022 May 23]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products."},{"key":"cit0068","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics [Internet]. 2018. [cited 2021 Oct 29]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone_en.pdf."},{"key":"cit0069","unstructured":"Food and drug administration. LEVAQUIN\u00a9 (levofloxacin) - label. Revised. [Internet]. 2013. [cited 2021 Aug 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020634s065,020635s071,021721s032lbl.pdf."},{"key":"cit0070","unstructured":"HealthCanada. Summary safety review - Fluoroquinolones - Assessing the potential risk of persistent and disabling side effects [Internet]. 2016. [cited 2021 Oct 29]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html."},{"key":"cit0071","unstructured":"Australian Government Department of Health Therapeutic Goods. Update - fluoroquinolone antibiotics and adverse events [Internet]. Ther. Goods Adm. TGA. Australian Government Department of Health; 2020. [cited 2022 Mar 28]. Available from: https:\/\/www.tga.gov.au\/publication-issue\/update-fluoroquinolone-antibiotics-and-adverse-events."},{"key":"cit0072","unstructured":"New Zealand\u2019s Medicines Adverse Reaction Committee. Assessment of the potential risk of disabling and persistent musculoskeletal and nervous system reactions from the use of fluoroquinolones. [Internet]. 2017. [cited 2022 Mar 28]. Available from: https:\/\/www.medsafe.govt.nz\/committees\/marc\/reports\/172-Fluoroquinolones_Redacted.pdf."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-209821"},{"key":"cit0074","unstructured":"Food and Drug Administration. FDA updates warnings for fluoroquinolone antibiotics [Internet]. FDA. FDA; 2020. [cited 2022 Jun 6]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-updates-warnings-fluoroquinolone-antibiotics."},{"key":"cit0075","unstructured":"Health Canada. Scientific advisory panel on anti-infective therapies (SAP-AIT) [Internet]. 2016. [cited 2022 May 12]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/scientific-expert-advisory-panels\/anti-infective-therapies\/announcement-meeting.html."},{"key":"cit0076","unstructured":"Fresenius Kabi Canada Inc. Moxifloxacin injection. Product monograph. [Internet]. 2017. [cited 2022 Mar 24]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00042564.PDF."},{"key":"cit0077","unstructured":"Teva Canada. Cipro - Product monograph. [Internet]. 2017. [cited 2022 Mar 24]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00042360.PDF."},{"key":"cit0078","unstructured":"Apotex Inc. APO - Levofloxacin. product monograph. [Internet]. 2018. [cited 2022 Mar 24]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00046102.PDF."},{"key":"cit0079","unstructured":"Health Canada. FLUOROQUINOLONES - Risk of disabling and persistent serious adverse reactions - Recalls, advisories and safety alerts [Internet]. Government of Canada, Health Canada, Marketed health products; 2021. [cited 2022 May 12]. Available from: https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/fluoroquinolones-risk-disabling-and-persistent-serious-adverse-reactions."},{"key":"cit0080","unstructured":"Health Canada. Information Update - Fluoroquinolone antibiotics may, in rare cases, cause persistent disabling side effects - Recalls, advisories and safety alerts [Internet]. Government of Canada, Health Canada, Communications and Public Affairs Branch; 2021. [cited 2022 May 12]. Available from: https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/information-update-fluoroquinolone-antibiotics-may-rare-cases-cause-persistent."},{"key":"cit0081","unstructured":"European Medicines Agency. Referral procedures [Internet]. Eur. Med. Agency. 2018. [cited 2022 Mar 28]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures."},{"key":"cit0082","unstructured":"PRAC. PRAC recommendations on signals - Adopted at the 3-6 September 2018 PRAC meeting [Internet]. 2018. [cited 2021 Oct 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-3-6-september-2018-prac-meeting_en-0.pdf."},{"key":"cit0083","unstructured":"Medicines Adverse Reactions Committee. FQs and aortic aneurysm\/dissection. [Internet]. 2019. [cited 2022 May 17]. Available from: https:\/\/www.medsafe.govt.nz\/committees\/marc\/reports\/178-3.2.3FluoroquinolonesAndAorticAneurysm.pdf."},{"key":"cit0084","unstructured":"Japanese Ministry of Health Labour and Welfare. Revisions of Precautions (Ciprofloxacin, Levofloxacin, and Moxifloxacin) [Internet]. 2019. [cited 2022 Mar 28]. Available from: https:\/\/www.pmda.go.jp\/files\/000227472.pdf."},{"key":"cit0085","unstructured":"Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients [Internet]. FDA. FDA; 2019. [cited 2021 Oct 28]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics."},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2017.06.029"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.06.067"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k678"},{"key":"cit0089","unstructured":"MARC Committee. MARC committee report on FQs. Dated June 13. [Internet]. 2019. [cited 2022 May 17]. Available from: https:\/\/www.medsafe.govt.nz\/committees\/marc\/reports\/178-3.2.3FluoroquinolonesAndAorticAneurysm.pdf."},{"key":"cit0090","volume-title":"AVELOX (moxifloxacin hydrochloride)","author":"Food and Drug Administration","year":"2016"},{"key":"cit0091","unstructured":"Health Canada. Summary Safety Review - Fluoroquinolones - Assessing the potential risk of aneurysm (a balloon-like bulge) and dissection (a separation or tear in the layers of the wall) of the aorta (a major blood vessel) [Internet]. 2016. [cited 2021 Oct 29]. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html."},{"key":"cit0092","unstructured":"Health Science Authority. Fluoroquinolones and risk of aortic aneurysm and dissection [Internet]. HSA. 2019. [cited 2022 Mar 24]. Available from: https:\/\/www.hsa.gov.sg\/announcements\/safety-alert\/fluoroquinolones-and-risk-of-aortic-aneurysm-and-dissection."},{"key":"cit0093","unstructured":"Electronic Medicines Compendium. Levofloxacin 500mg Film-coated tablets - Summary of Product characteristics. Revised [Internet]. 2015. [cited 2022 Mar 24]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4625\/smpc#gref."},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-018-4774-2"},{"key":"cit0095","unstructured":"Australian Government Department of Health Therapeutic Goods. Fluoroquinolone antibiotics and risk of aortic aneurysm\/dissection [Internet]. Ther. Goods Adm. TGA. Australian Government Department of Health; 2019. [cited 2021 Oct 29]. Available from: https:\/\/www.tga.gov.au\/publication-issue\/fluoroquinolone-antibiotics-and-risk-aortic-aneurysmdissection."},{"key":"cit0096","unstructured":"European Medicines Agency. Systemic and inhaled fluoroquinolones: risk of heart valve regurgitation\/incompetence [Internet]. Eur. Med. Agency. 2020. [cited 2022 Jun 6]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/systemic-inhaled-fluoroquinolones-risk-heart-valve-regurgitationincompetence."},{"key":"cit0097","unstructured":"Medicines and Health Regulatory Authority. Drug safety update: FQ associated risk of heart valve regurgitation\/incompetence. [Internet]. GOV.UK. 2018. [cited 2022 May 17]. Available from: https:\/\/www.gov.uk\/drug-safety-update."},{"key":"cit0098","unstructured":"Health Science Authority. Risk of heart valve regurgitation with fluoroquinolones [Internet]. 2021. [cited 2022 Jun 6]. Available from: https:\/\/www.hsa.gov.sg\/announcements\/safety-alert\/risk-of-heart-valve-regurgitation-with-fluoroquinolones."},{"key":"cit0099","unstructured":"British Generic Manufacturers Association. Direct healthcare professional communication on systemic and inhaled fluoroquinolones: risk of heart valve regurgitation\/incompetence. [Internet]. 2020. [cited 2022 May 17]. Available from: https:\/\/assets.publishing.service.gov.uk\/media\/5ff59241e90e0776aa14132a\/Fluoroquinolones_DHCP_09-12.pdf."},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.035"},{"key":"cit0101","unstructured":"Bennett A, Qureshi Z, Bennett C. A novel genetic marker has been identified in patients with fluoroquinolone-associated neuropsychiatric toxicity: preliminary findings. Abstr 55 2017 AVAHO Meet [Internet]. [cited 2021 Oct 28]; Available from: https:\/\/www.mdedge.com\/fedprac\/avaho\/article\/146822\/novel-genetic-marker-has-been-identified-patients-fluoroquinolone."}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2022.2147924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:06:23Z","timestamp":1672131983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2022.2147924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,2]]}},"alternative-id":["10.1080\/14740338.2022.2147924"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2022.2147924","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}